Exclusive Interview: Perceptive Advisors Launches LianBio with a New Model to Take US Assets to China

Perceptive Advisors is launching LianBio to bring US biopharma assets to China. A successful fund operator, Perceptive has made investments in 150 public and 80 private biopharmas and has strong connections to them. With a paradigm-shifting assets and top drug developers in China, LianBio plans to build a strong China portfolio. Dr. Debra Yu, MD, President and Chief Business Officer of LianBio, told ChinaBio® Today in an exclusive interview, "Our unique feature is – we are moving beyond mere innovation to focus on paradigm shifting medicines, leveraging Perceptive's relationships into biotech’s high flyers." We talked with Perceptive's and LianBio's teams to learn more about them and their China plans . More details.... Share this with colleagues: // //